U.S. FDA issues warning letter to Zydus Lifesciences’ Baddi formulation unit
The U.S. FDA issued a warning letter to Zydus Lifesciences regarding technical issues with purified talc at their Baddi manufacturing facility. The company stated that the letter does not impact current operations or supply chains.
Why it matters
Regulatory warnings for pharmaceutical manufacturers can impact drug safety standards and international supply chain stability.
The U.S. Food and Drug Administration (U.S. FDA) has issued a warning letter to Zydus Lifesciences relating to the company’s formulation manufacturing facility in Baddi, Himachal Pradesh.
The report relies on company filings and regulatory facts without editorializing the impact.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in